Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody, which binds to
circulating soluble IL-6 receptor and membrane-expressed IL-6 receptor, inhibiting IL-6 …

We present safety and efficacy data from Japanese clinical studies on monotherapy with
tocilizumab (TCZ), a humanized anti-interleukin 6 receptor monoclonal antibody, in which …

BACKGROUND: Tocilizumab (TCZ), a humanized anti–interleukin-6 receptor monoclonal
antibody, represents a new treatment strategy for patients with rheumatoid arthritis (RA) and …

Recent years have seen many exciting developments in the treatment of rheumatoid
arthritis. Tocilizumab (TCZ) is a monoclonal antibody which inhibits the interleukin-6 …

Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid
arthritis (RA). It was developed in 2008, and its effectiveness is supported by evidence from …

Recent developments in understanding the immunopathogenesis of rheumatoid arthritis
(RA), combined with progress in biopharmaceutical development, have facilitated the …

Objectives. To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical
practice. Methods. We observed 232 consecutive RA patients who began tocilizumab in …

Objective. To compare the benefit and safety of tocilizumab to placebo in patients with
rheumatoid arthritis (RA). Methods. We searched multiple databases for published …

The introduction of biological agents targeting tumor necrosis factor-alpha (TNF-α) has
brought about a paradigm shift in the treatment of rheumatoid arthritis (RA). Although these …

Background Tocilizumab, a new biologic that inhibits interleukin‐6, is approved for treatment
of rheumatoid arthritis (RA) in Europe, Japan and the US. Objectives To assess the efficacy …